Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
drug delivery
eye
nanoformulation
ocular barriers
polymers
posterior segment
Journal
AAPS PharmSciTech
ISSN: 1530-9932
Titre abrégé: AAPS PharmSciTech
Pays: United States
ID NLM: 100960111
Informations de publication
Date de publication:
27 Oct 2023
27 Oct 2023
Historique:
received:
11
08
2023
accepted:
03
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
The eye, an intricate organ comprising physical and physiological barriers, poses a significant challenge for ophthalmic physicians seeking to treat serious ocular diseases affecting the posterior segment, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR). Despite extensive efforts, the delivery of therapeutic drugs to the rear part of the eye remains an unresolved issue. This comprehensive review delves into conventional and innovative formulation strategies for drug delivery to the posterior segment of the eye. By utilizing alternative nanoformulation approaches such as liposomes, nanoparticles, and microneedle patches, researchers and clinicians can overcome the limitations of conventional eye drops and achieve more effective drug delivery to the posterior segment of the eye. These innovative strategies offer improved drug penetration, prolonged residence time, and controlled release, enhancing therapeutic outcomes for ocular diseases. Moreover, this article explores recently approved delivery systems that leverage diverse polymer technologies, such as chitosan and hyaluronic acid, to regulate drug-controlled release over an extended period. By offering a comprehensive understanding of the available formulation strategies, this review aims to empower researchers and clinicians in their pursuit of developing highly effective treatments for posterior-segment ocular diseases.
Identifiants
pubmed: 37891392
doi: 10.1208/s12249-023-02673-x
pii: 10.1208/s12249-023-02673-x
doi:
Substances chimiques
Delayed-Action Preparations
0
Liposomes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
217Informations de copyright
© 2023. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Références
Wang Y, Wang C. Novel eye drop delivery systems: advance on formulation design strategies targeting anterior and posterior segments of the eye. Pharmaceutics. 2022;14:1150.
pubmed: 35745723
pmcid: 9229693
doi: 10.3390/pharmaceutics14061150
Garkal A, Bangar P, Rajput A, Pingale P, Dhas N, Sami A, et al. Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED. J Control Release. 2022;350:538–68.
pubmed: 36030993
doi: 10.1016/j.jconrel.2022.08.040
Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. Drug Discov Today. 2011;16:270–7.
pubmed: 21167306
doi: 10.1016/j.drudis.2010.12.004
Das A. Diabetic retinopathy: battling the global epidemic. Investig Ophthalmol Vis Sci. 2016;57:6669–82.
doi: 10.1167/iovs.16-21031
Silva M, Peng T, Zhao X, Li S, Farhan M, Zheng W. Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis. Adv Drug Deliv Rev. 2021;173:439–60.
pubmed: 33857553
doi: 10.1016/j.addr.2021.04.007
Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6:422–37.
pubmed: 24888969
pmcid: 4155159
doi: 10.1002/wnan.1272
Bisht R, Mandal A, Jaiswal JK, Rupenthal ID. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018;10:e1473.
doi: 10.1002/wnan.1473
Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther. 2016;32:67–82.
pubmed: 26666398
doi: 10.1089/jop.2015.0047
Biswas A, Choudhury AD, Agrawal S, Bisen AC, Sanap SN, Verma SK, Kumar M, Mishra A, Kumar S, Chauhan M, Bhatta RS. Recent insights into the etiopathogenesis of diabetic retinopathy and its management. J Ocul Pharmacol Ther. https://doi.org/10.1089/jop.2023.0068
Djebli N, Khier S, Griguer F, Coutant A-L, Tavernier A, Fabre G, et al. Ocular drug distribution after topical administration: population pharmacokinetic model in rabbits. Eur J Drug Metab Pharmacokinet. 2017;42:59–68.
pubmed: 26820265
doi: 10.1007/s13318-016-0319-4
Wang R, Gao Y, Liu A, Zhai G. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances. J Drug Target. 2021;29:687–702.
pubmed: 33474998
doi: 10.1080/1061186X.2021.1878366
Suri R, Beg S, Kohli K. Target strategies for drug delivery bypassing ocular barriers. J Drug Deliv Sci Technol. 2020;55: 101389.
doi: 10.1016/j.jddst.2019.101389
Kim HM, Woo SJ. Ocular drug delivery to the retina: current innovations and future perspectives. Pharmaceutics. 2021;13:1–32.
Jiang S, Franco YL, Zhou Y, Chen J. Nanotechnology in retinal drug delivery. Int J Ophthalmol. 2018;11:1038–44.
pubmed: 29977820
pmcid: 6010371
Janagam DR, Wu L, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev. 2017;122:31–64.
pubmed: 28392306
pmcid: 6057481
doi: 10.1016/j.addr.2017.04.001
Mandal A, Pal D, Agrahari V, Trinh HM, Joseph M, Mitra AK. Ocular delivery of proteins and peptides: challenges and novel formulation approaches. Adv Drug Deliv Rev. 2018;126:67–95.
pubmed: 29339145
pmcid: 5995646
doi: 10.1016/j.addr.2018.01.008
Patel JK, Sutariya V, Kanwar JR, Pathak Y V. Drug delivery for the retina and posterior segment disease. Springer; 2018.
Bisht R, Mandal A, Jaiswal JK, Rupenthal ID. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018;10:1–21.
doi: 10.1002/wnan.1473
Cholkar K, Dasari SR, Pal D, Mitra AK. Eye: Anatomy, physiology and barriers to drug delivery. Ocul Transp Recept. Elsevier; 2013. p. 1–36.
Gorantla S, Rapalli VK, Waghule T, Singh PP, Dubey SK, Saha RN, et al. Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv. 2020;10:27835–55.
pubmed: 35516960
pmcid: 9055630
doi: 10.1039/D0RA04971A
Kumar D, Jain N, Gulati N, Nagaich U. Nanoparticles laden in situ gelling system for ocular drug targeting. J Adv Pharm Technol Res. 2013;4:9–17.
pubmed: 23662277
pmcid: 3645361
doi: 10.4103/2231-4040.107495
Nisha S, Deepak K. An insight to ophtalmic drug delivery system. Int J Pharm Stud Res. 2012;3:9–13.
Lee J, Pelis RM. Drug transport by the blood-aqueous humor barrier of the eye. Drug Metab Dispos. 2016;44:1675–81.
pubmed: 26895982
doi: 10.1124/dmd.116.069369
Kuno N, Fujii S. Recent advances in ocular drug delivery systems. Polymers (Basel). 2011;3:193–221.
doi: 10.3390/polym3010193
Booij JC, Baas DC, Beisekeeva J, Gorgels TGMF, Bergen AAB. The dynamic nature of Bruch’s membrane. Prog Retin Eye Res. 2010;29:1–18.
pubmed: 19747980
doi: 10.1016/j.preteyeres.2009.08.003
Watson PG, Young RD. Scleral structure, organisation and disease. A review Exp Eye Res. 2004;78:609–23.
pubmed: 15106941
doi: 10.1016/S0014-4835(03)00212-4
Coudrillier B, Pijanka J, Jefferys J, Sorensen T, Quigley HA, Boote C, et al. Collagen structure and mechanical properties of the human sclera: analysis for the effects of age. J Biomech Eng. 2015;137:41006.
doi: 10.1115/1.4029430
Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82:479–87.
pubmed: 16168412
doi: 10.1016/j.exer.2005.08.007
Peynshaert K, Devoldere J, De Smedt SC, Remaut K. In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye. Adv Drug Deliv Rev. 2018;126:44–57.
pubmed: 28939376
doi: 10.1016/j.addr.2017.09.007
Varela-Fernández R, Díaz-Tomé V, Luaces-Rodríguez A, Conde-Penedo A, García-Otero X, Luzardo-álvarez A, et al. Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations. Pharmaceutics. 2020;12:1–39.
doi: 10.3390/pharmaceutics12030269
Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21:3–9.
doi: 10.5301/EJO.2010.6049
Díaz-Coránguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: cellular basis and development. Vision Res. 2017;139:123–37.
pubmed: 28619516
pmcid: 5723228
doi: 10.1016/j.visres.2017.05.009
Campbell M, Humphries P. The blood-retina barrier tight junctions and barrier modulation. Adv Exp Med Biol. 2013;763:70–84.
doi: 10.1007/978-1-4614-4711-5_3
Kim YC, Chiang B, Wu X, Prausnitz MR. Ocular delivery of macromolecules. J Control Release. 2014;190:172–81.
pubmed: 24998941
doi: 10.1016/j.jconrel.2014.06.043
Alshaikh RA, Waeber C, Ryan KB. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies. Adv Drug Deliv Rev. 2022;187:114342.
pubmed: 35569559
doi: 10.1016/j.addr.2022.114342
Kim S, Kim J-H, Jeon O, Kwon IC, Park K. Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm. 2009;71:420–30.
pubmed: 18977434
doi: 10.1016/j.ejpb.2008.09.021
Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Investig Ophthalmol Vis Sci. 2003;44:2702–7.
doi: 10.1167/iovs.02-0956
Okabe J, Kimura H, Kunou N, Okabe K, Kato A, Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Investig Ophthalmol Vis Sci. 2003;44:740–4.
doi: 10.1167/iovs.02-0375
Van Hove AH, Benoit DSW. Depot-based delivery systems for pro-angiogenic peptides: a review. Front Bioeng Biotechnol. 2015;3:1–18.
Khiev D, Mohamed ZA, Vichare R, Paulson R, Bhatia S, Mohapatra S, et al. Emerging nano-formulations and nanomedicines applications for ocular drug delivery. Nanomaterials. 2021;11:1–19.
doi: 10.3390/nano11010173
Qamar Z, Qizilbash FF, Iqubal MK, Ali A, Narang JK, Ali J, et al. Nano-based drug delivery system: recent strategies for the treatment of ocular disease and future perspective. Recent Pat Drug Deliv Formul. 2019;13:246–54.
pubmed: 31884933
pmcid: 7499345
doi: 10.2174/1872211314666191224115211
Zhang J, Jiao J, Niu M, Gao X, Zhang G, Yu H, et al. Ten years of knowledge of nano-carrier based drug delivery systems in ophthalmology: current evidence, challenges, and future prospective. Int J Nanomedicine. 2021;16:6497–530.
pubmed: 34588777
pmcid: 8473849
doi: 10.2147/IJN.S329831
Chingunpituk J. Nanosuspension technology for drug delivery. Walailak J Sci Tech. 2007;4:139–53.
Wang X, Wang S, Zhang Y. Advance of the application of nano-controlled release system in ophthalmic drug delivery. Drug Deliv. 2016;23:2897–901.
pubmed: 26635087
doi: 10.3109/10717544.2015.1116025
Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2010;56:827–40.
doi: 10.1211/0022357023691
Garnett E, Mai L, Yang P. Introduction: 1D nanomaterials/nanowires. Chem Rev. 2019;119:8955–7.
pubmed: 31409075
doi: 10.1021/acs.chemrev.9b00423
Delcassian D, Patel AK, Cortinas AB, Langer R. Drug delivery across length scales. J Drug Target. 2019;27:229–43.
pubmed: 29415575
doi: 10.1080/1061186X.2018.1438440
Christiansen AT, Tao SL, Smith M, Wnek GE, Prause JU, Young MJ, et al. Subretinal implantation of electrospun, short nanowire, and smooth poly(ε-caprolactone) Scaffolds to the Subretinal Space of Porcine Eyes. Stem Cells Int. 2012; 2012.
Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002;28:1–13.
pubmed: 11858519
doi: 10.1081/DDC-120001481
Hee DH, Da EN, Dong HS, Tae WK, Byung CS, Ho SC. Preparation and biodegradation of thermosensitive chitosan hydrogel as a function of pH and temperature. Macromol Res. 2004;12:507–11.
doi: 10.1007/BF03218435
Abrego G, Alvarado H, Souto EB, Guevara B, Bellowa LH, Parra A, et al. Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration. Eur J Pharm Biopharm. 2015;95:261–70.
pubmed: 25681744
doi: 10.1016/j.ejpb.2015.01.026
Barar J, Aghanejad A, Fathi M, Omidi Y. Advanced drug delivery and targeting technologies for the ocular diseases. BioImpacts. 2016;6:49–67.
pubmed: 27340624
pmcid: 4916551
doi: 10.15171/bi.2016.07
da Silva R, Fialho SL, Siqueira RC, Jorge R, da Silva Cunha Júnior A. Implants as drug delivery devices for the treatment of eye diseases. Brazilian J Pharm Sci. 2010;46:585–95.
Bourges JL, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev. 2006;58:1182–202.
pubmed: 17107737
doi: 10.1016/j.addr.2006.07.026
Eljarrat-Binstock E, Pe’er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27:530–43.
pubmed: 20155388
doi: 10.1007/s11095-009-0042-9
Janoria KG, Gunda S, Boddu SHS, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007;4:371–88.
pubmed: 17683251
doi: 10.1517/17425247.4.4.371
Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD, Group GIS. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med. 1997;337:83–90.
doi: 10.1056/NEJM199707103370203
Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y. Drug delivery from ocular implants. Expert Opin Drug Deliv. 2006;3:261–73.
pubmed: 16506952
doi: 10.1517/17425247.3.2.261
del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008;13:135–43.
Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27:2043–53.
pubmed: 20535532
doi: 10.1007/s11095-010-0159-x
Jiang J, Gill HS, Ghate D, McCarey BE, Patel SR, Edelhauser HF, et al. Coated microneedles for drug delivery to the eye. Investig Ophthalmol Vis Sci. 2007;48:4038–43.
doi: 10.1167/iovs.07-0066
Thakur Singh RR, Tekko I, McAvoy K, McMillan H, Jones D, Donnelly RF. Minimally invasive microneedles for ocular drug delivery. Expert Opin Drug Deliv. 2017;14:525–37.
pubmed: 27485251
doi: 10.1080/17425247.2016.1218460
Jung JH, Chiang B, Grossniklaus HE, Prausnitz MR. Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle. J Control Release. 2018;277:14–22.
pubmed: 29505807
pmcid: 5911252
doi: 10.1016/j.jconrel.2018.03.001
Lee KJ, Song HB, Cho W, Kim JH, Kim JH, Ryu WH. Intracorneal injection of a detachable hybrid microneedle for sustained drug delivery. Acta Biomater. 2018;80:48–57.
pubmed: 30267886
doi: 10.1016/j.actbio.2018.09.039
Park SH, Jo DH, Cho CS, Lee KJ, Kim JH, Ryu S, et al. Depthwise-controlled scleral insertion of microneedles for drug delivery to the back of the eye. Eur J Pharm Biopharm. 2018;133:31–41.
pubmed: 30267835
doi: 10.1016/j.ejpb.2018.09.021
Patel SR, Berezovsky DE, McCarey BE, Zarnitsyn V, Edelhauser HF, Prausnitz MR. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Investig Ophthalmol Vis Sci. 2012;53:4433–41.
doi: 10.1167/iovs.12-9872
Biswal MR, Bhatia S. Carbon dot nanoparticles: exploring the potential use for gene delivery in ophthalmic diseases. Nanomaterials. 2021;11:1–12.
doi: 10.3390/nano11040935
Wang L, Pan H, Gu D, Sun H, Chen K, Tan G, et al. A novel carbon dots/thermo-sensitive in situ gel for a composite ocular drug delivery system: characterization, ex-vivo imaging, and in vivo evaluation. Int J Mol Sci. 2021;22:9934.
pubmed: 34576093
pmcid: 8464813
doi: 10.3390/ijms22189934
Zhang Y, Han L, Zhang Y, Chang YQ, Chen XW, He RH, et al. Glutathione-mediated mesoporous carbon as a drug delivery nanocarrier with carbon dots as a cap and fluorescent tracer. Nanotechnology. 2016;27:1–9.
doi: 10.1088/0957-4484/27/35/355102
Sharma DS, Wadhwa S, Gulati M, Kadukkattil Ramanunny A, Awasthi A, Singh SK, et al. Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy. Expert Opin Drug Deliv. 2021;18:553–76.
pubmed: 33143473
doi: 10.1080/17425247.2021.1846518
Bian F, Shin CS, Wang C, Pflugfelder SC, Acharya G, de Paiva CS. Dexamethasone drug eluting nanowafers control inflammation in alkali-burned corneas associated with dry eye. Investig Ophthalmol Vis Sci. 2016;57:3222–30.
doi: 10.1167/iovs.16-19074
Sivaram AJ, Rajitha P, Maya S, Jayakumar R, Sabitha M. Nanogels for delivery, imaging and therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7:509–33.
pubmed: 25581024
doi: 10.1002/wnan.1328
Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention. Drug Deliv. 2013;20:306–9.
pubmed: 24044648
doi: 10.3109/10717544.2013.838712
Sepahvandi A, Eskandari M, Moztarzadeh F. Drug delivery systems to the posterior segment of the eye: implants and nanoparticles. Bionanoscience. 2016;6:276–83.
doi: 10.1007/s12668-016-0219-8
Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013;36:172–98.
pubmed: 23603534
pmcid: 3926814
doi: 10.1016/j.preteyeres.2013.04.001
Karim K, Mandal A, Biswas N, Guha A, Chatterjee S, Behera M, et al. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res. 2010;1:374–80.
doi: 10.4103/0110-5558.76435
Shastri DH, Silva AC, Almeida H. Ocular delivery of therapeutic proteins: a review. Pharmaceutics. 2023;15:205.
pubmed: 36678834
pmcid: 9864358
doi: 10.3390/pharmaceutics15010205
Puras G, Martínez-Navarrete G, Mashal M, Zárate J, Agirre M, Ojeda E, et al. Protamine/DNA/niosome ternary nonviral vectors for gene delivery to the retina: the role of protamine. Mol Pharm. 2015;12:3658–71.
pubmed: 26334586
doi: 10.1021/acs.molpharmaceut.5b00422
Elsaid N, Somavarapu S, Jackson TL. Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus. Exp Eye Res. 2014;121:121–9.
pubmed: 24530465
doi: 10.1016/j.exer.2014.02.001
Rajala A, Wang Y, Zhu Y, Ranjo-Bishop M, Ma JX, Mao C, et al. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo. Nano Lett. 2014;14:5257–63.
pubmed: 25115433
pmcid: 4160266
doi: 10.1021/nl502275s
Campos EJ, Campos A, Martins J, Ambrósio AF. Opening eyes to nanomedicine: where we are, challenges and expectations on nanotherapy for diabetic retinopathy. Nanomed Nanotechnol Biol Med. 2017;13:2101–13.
doi: 10.1016/j.nano.2017.04.008
Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Rel. 2009;136:2–13.
doi: 10.1016/j.jconrel.2008.12.018
Li Q, Weng J, Wong SN, Thomas Lee WY, Chow SF. Nanoparticulate drug delivery to the retina. Mol Pharm. 2021;18:506–21.
pubmed: 32501716
doi: 10.1021/acs.molpharmaceut.0c00224
Sanap SN, Bisen AC, Mishra A, Biswas A, Agrawal S, Yadav KS, Krishna A, Chopra S, Mugale MN, Bhatta RS. QbD based antifungal drug-loaded ophthalmic liposomal formulation for the management of fungal keratitis: In vitro, ex vivo and in vivo pharmacokinetic studies. J Drug Delivery Sci Technol. 2022;74:103517. https://doi.org/10.1016/j.jddst.2022.103517
Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother. 2018;107:1564–82.
pubmed: 30257375
doi: 10.1016/j.biopha.2018.08.138
Ramos-Cabrer P, Campos F. Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomed. 2013;8:951–60.
doi: 10.2147/IJN.S30721
Sapra P, Tyagi P, Allen T. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005;2:369–81.
pubmed: 16305440
doi: 10.2174/156720105774370159
Hagigit T, Abdulrazik M, Orucov F, Valamanesh F, Lambert M, Lambert G, et al. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J Control Release. 2010;145:297–305.
pubmed: 20420865
doi: 10.1016/j.jconrel.2010.04.013
Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21:15–34.
pubmed: 11906809
doi: 10.1016/S1350-9462(01)00017-9
Bhanushali RS, Gatne MM, Gaikwad RV, Bajaj AN, Morde MA. Nanoemulsion based intranasal delivery of antimigraine drugs for nose to brain targeting. Indian J Pharm Sci. 2009;71:707–9.
pmcid: 2846483
Pawar VK, Panchal SB, Singh Y, Meher JG, Sharma K, Singh P, et al. Immunotherapeutic vitamin e nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response. J Control Release. 2014;196:295–306.
pubmed: 25459427
doi: 10.1016/j.jconrel.2014.10.010
Khani S, Keyhanfar F, Amani A. Design and evaluation of oral nanoemulsion drug delivery system of mebudipine. Drug Deliv. 2016;23:2035–43.
pubmed: 26406153
doi: 10.3109/10717544.2015.1088597
Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;252:28–49.
pubmed: 28279798
doi: 10.1016/j.jconrel.2017.03.008
Phytosomes BS. PORACOM Academic Publishers Phytosomes: the new technology for enhancement of bioavailability of botanicals and nutraceuticals. Int J Heal Res. 2009;2:224–5.
Navarro-Partida J, Castro-Castaneda CR, Cruz-Pavlovich FJS, Aceves-Franco LA, Guy TO, Santos A. Lipid-based nanocarriers as topical drug delivery systems for intraocular diseases. Pharmaceutics. 2021;13:1–25.
doi: 10.3390/pharmaceutics13050678
Lalu L, Tambe V, Pradhan D, Nayak K, Bagchi S, Maheshwari R, et al. Novel nanosystems for the treatment of ocular inflammation: current paradigms and future research directions. J Control Release. 2017;268:19–39.
pubmed: 28756272
doi: 10.1016/j.jconrel.2017.07.035
Karami Z, Hamidi M. Cubosomes: remarkable drug delivery potential. Drug Discov Today. 2016;21:789–801.
pubmed: 26780385
doi: 10.1016/j.drudis.2016.01.004
Burhan AM, Klahan B, Cummins W, Andrés-Guerrero V, Byrne ME, O’reilly NJ, et al. Posterior segment ophthalmic drug delivery: role of muco-adhesion with a special focus on chitosan. Pharmaceutics. 2021;13(10):1685.
pubmed: 34683978
pmcid: 8539343
doi: 10.3390/pharmaceutics13101685
Chopra P, Hao J, Li SK. Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera. J Control Release. 2012;160:96–104.
pubmed: 22306336
pmcid: 3372542
doi: 10.1016/j.jconrel.2012.01.032
Vadlapudi AD, Cholkar K, Vadlapatla RK, Mitra AK. Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility. J Ocul Pharmacol Ther. 2014;30:49–58.
pubmed: 24192229
pmcid: 4066223
doi: 10.1089/jop.2013.0157
Mandal A, Gote V, Pal D, Ogundele A, Mitra AK. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa®) for dry eye disease. Pharm Res. 2019;36.
Mandal A, Bisht R, Rupenthal ID, Mitra AK. Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. J Control Release. 2017;248:96–116.
pubmed: 28087407
pmcid: 5319397
doi: 10.1016/j.jconrel.2017.01.012
Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed Nanotechnol Biol Med. 2010;6:714–29.
doi: 10.1016/j.nano.2010.05.005
Ameeduzzafar A, Ali J, Fazil M, Qumbar M, Khan N, Ali A. Colloidal drug delivery system: amplify the ocular delivery. Drug Deliv. 2016;23:710–26.
doi: 10.3109/10717544.2014.923065
Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102:23–38.
pubmed: 15653131
doi: 10.1016/j.jconrel.2004.09.015
Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370:602–24.
pubmed: 31072813
doi: 10.1124/jpet.119.256933
Bhargava N, Shanmugaiah V, Saxena M, Sharma M, Sethy NK, Singh SK, et al. Nanocerium oxide increases the survival of adult rod and cone photoreceptor in culture by abrogating hydrogen peroxide-induced oxidative stress. Biointerphases. 2016;11:031016.
pubmed: 27782496
doi: 10.1116/1.4962263
de Araújo RV, da Silva Santos S, Ferreira EI, Giarolla J. New advances in general biomedical applications of PAMAM dendrimers. Molecules. 2018;23:1–27.
doi: 10.3390/molecules23112849
Ikuta Y, Aoyagi S, Tanaka Y, Sato K, Inada S, Koseki Y, et al. Creation of nano eye-drops and effective drug delivery to the interior of the eye. Sci Rep. 2017;7:1–10.
doi: 10.1038/srep44229
Kambhampati SP, Mishra MK, Mastorakos P, Oh Y, Lutty GA, Kannan RM. Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells. Eur J Pharm Biopharm. 2015;95:239–49.
pubmed: 25701805
pmcid: 4861086
doi: 10.1016/j.ejpb.2015.02.013
Rieke ER, Amaral J, Becerra SP, Lutz RJ. Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J Ocul Pharmacol Ther. 2010;26:55–64.
pubmed: 20148655
pmcid: 3096542
doi: 10.1089/jop.2009.0059
Patel A. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2:47.
pubmed: 25590022
pmcid: 4289909
doi: 10.5497/wjp.v2.i2.47
Bisht R, Nirmal S, Agrawal R, Jain GK, Nirmal J. Injectable in-situ gel depot system for targeted delivery of biologics to the retina. J Drug Target. 2021;29:46–59.
pubmed: 32729731
doi: 10.1080/1061186X.2020.1803886
Gandhi A, Paul A, Sen SO, Sen KK. Studies on thermoresponsive polymers: phase behaviour, drug delivery and biomedical applications. Asian J Pharm Sci. 2015;10:99–107.
doi: 10.1016/j.ajps.2014.08.010
Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J, et al. Research progress of in-situ gelling ophthalmic drug delivery system. Asian J Pharm Sci. 2019;14:1–15.
pubmed: 32104434
doi: 10.1016/j.ajps.2018.04.008
Vigani B, Rossi S, Sandri G, Bonferoni MC, Caramella CM, Ferrari F. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes. Pharmaceutics. 2020;12:1–29.
doi: 10.3390/pharmaceutics12090859
Saraf SA, Alexander A, Khan J, Giri TK, Tripathi DK, et al. Advancement in stimuli triggered in situ gelling delivery for local and systemic route. Expert Opin Drug Deliv. 2012;9:1573–92.
pubmed: 23075325
doi: 10.1517/17425247.2013.734806
Venkatraman S, Joseph RR, Boey YCF. Subconjunctival depot forming formulations for ocular drug delivery. Google Patents; 2019. https://patents.google.com/patent/EP3445335A4/en
Venkatraman et al. Stable liposomal formulations for ocular drug delivery. Google Patents; 2015. https://patents.google.com/patent/US20150190359A1/en
Tundisi LL, Mostaço GB, Carricondo PC, Petri DFS. Hydroxypropyl methylcellulose: physicochemical properties and ocular drug delivery formulations. Eur J Pharm Sci. 2021;159:105736.
pubmed: 33516807
doi: 10.1016/j.ejps.2021.105736
Souto EB, Dias-Ferreira J, López-Machado A, Ettcheto M, Cano A, Espuny AC, et al. Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents. Pharmaceutics. 2019;11:1–29.
doi: 10.3390/pharmaceutics11090460
Vadlapudi AD, Patel A, Cholkar K, Mitra AK. Recent patents on emerging therapeutics for the treatment of glaucoma, age related macular degeneration and uveitis. Recent Pat Biomed Eng. 2012;5:83–101.
pubmed: 25414810
pmcid: 4235159
doi: 10.2174/1874764711205010083
Timmins P. Industry update: the latest developments in the field of therapeutic delivery, August 2022. Ther Deliv. 2022;13:429–44.
doi: 10.4155/tde-2022-0053
García-Estrada P, García-Bon MA, López-Naranjo EJ, Basaldúa-Pérez DN, Santos A, Navarro-Partida J. Polymeric implants for the treatment of intraocular eye diseases: trends in biodegradable and non-biodegradable materials. Pharmaceutics. 2021;13:701.
pubmed: 34065798
pmcid: 8151640
doi: 10.3390/pharmaceutics13050701
Shen HH, Chan EC, Lee JH, Bee YS, Lin TW, Dusting GJ, et al. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery. Nanomedicine. 2015;10:2093–107.
pubmed: 26096379
doi: 10.2217/nnm.15.47
Grumezescu AM. Design of nanostructures for versatile therapeutic applications. Des Nanostructures Versatile Ther Appl. William Andrew; 2018. p. 1–663.
Aukunuru J, Tyagi P, Durairaj C, Kompella UB. Drug suspension development for the back of the eye. Drug Prod Dev Back Eye. Springer; 2011. p. 449–68.
Pooja D, Kadari A, Kulhari H, Sistla R. Lipid-based nanomedicines: current clinical status and future perspectives. Lipid Nanocarriers Drug Target. Elsevier; 2018. p. 509–28.
Kang-Mieler JJ, Rudeen KM, Liu W, Mieler WF. Advances in ocular drug delivery systems. Eye. 2020;34:1371–9.
pubmed: 32071402
pmcid: 7376171
doi: 10.1038/s41433-020-0809-0
Shahiwala A. Applications of polymers in ocular drug delivery. Appl Polym Drug Deliv. INC; 2020. p. 355–92.
Robbie SJ, von Leithner PL, Ju M, Lange CA, King AG, Adamson P, et al. Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease. Investig Ophthalmol Vis Sci. 2013;54:1490–500.
doi: 10.1167/iovs.12-10169
Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127:186–95.
pubmed: 31474439
doi: 10.1016/j.ophtha.2019.07.011
Zhu C, Zhang Y, Pardridge WM. Widespread expression of an exogenous gene in the eye after intravenous administration. Investig Ophthalmol Vis Sci. 2002;43:3075–80.
Rimpelä AK, Reinisalo M, Hellinen L, Grazhdankin E, Kidron H, Urtti A, et al. Implications of melanin binding in ocular drug delivery. Adv Drug Deliv Rev. 2018;126:23–43.
pubmed: 29247767
doi: 10.1016/j.addr.2017.12.008
Diaferia C, Morelli G, Accardo A. Fmoc-diphenylalanine as a suitable building block for the preparation of hybrid materials and their potential applications. J Mater Chem B. 2019;7:5142–55.
pubmed: 31380554
doi: 10.1039/C9TB01043B
Cespi M, Casettari L, Palmieri GF, Perinelli DR, Bonacucina G. Rheological characterization of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®) water dispersions. Colloid Polym Sci. 2014;292:235–41.
doi: 10.1007/s00396-013-3077-8
Lakshman D, Chegireddy M, Hanegave GK, Sree KN, Kumar N, Lewis SA, et al. Investigation of drug-polymer miscibility, biorelevant dissolution, and bioavailability improvement of Dolutegravir-polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solid dispersions. Eur J Pharm Sci. 2020;142:105137.
pubmed: 31706016
doi: 10.1016/j.ejps.2019.105137
Sun F, Zheng Z, Lan J, Li X, Li M, Song K, et al. New micelle myricetin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment. Drug Deliv. 2019;26:575–85.
pubmed: 31172843
pmcid: 6567238
doi: 10.1080/10717544.2019.1622608
Koutsoviti M, Siamidi A, Pavlou P, Vlachou M. Recent advances in the excipients used for modified ocular drug delivery. Materials (Basel). 2021;14:4290.
pubmed: 34361483
pmcid: 8347600
doi: 10.3390/ma14154290
Hu KK, Hui YN, Du HJ. Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Int Eye Sci. 2022;22:1992–6.
Iovino C, Mastropasqua R, Lupidi M, Bacherini D, Pellegrini M, Bernabei F, et al. Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: a comprehensive review of the literature. Pharmaceutics. 2020;12:1–26.
doi: 10.3390/pharmaceutics12080703
Mochizuki M, Ikeda E, Yoshimura K, Hikita N, Nagata Y, Iwamoto A, et al. Treatment of cytomegalovirus retinitis in AIDS with an intraocular sustained-release ganciclovir implant. J Japanese Ophthalmol Soc. 1998;102:515–21.
Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol. 2003;87:361.
pubmed: 12598455
pmcid: 1771553
doi: 10.1136/bjo.87.3.361
Sangwan VS, Pearson PA, Paul H, Comstock TL. Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther. 2015;4:1–19.
pubmed: 25502122
doi: 10.1007/s40123-014-0027-6
Hikal M, Celik N, Auffarth GU, Khoramnia R, Kessler LJ, Mayer CS. Intravitreal 0.19 mg fluocinolone acetonide implant in non-infectious uveitis. J Clin Med. 2021;10:3966.
pubmed: 34501414
pmcid: 8432003
doi: 10.3390/jcm10173966
Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118:1580–7.
pubmed: 21813090
doi: 10.1016/j.ophtha.2011.02.048
Sudhalkar A, Vasavada A, Bhojwani D, Vasavada V, Vasavada S, Vasavada V, et al. Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial. Eye. 2020;34:491–8.
pubmed: 31320735
doi: 10.1038/s41433-019-0534-8
Allyn MM, Luo RH, Hellwarth EB, Swindle-Reilly KE. Considerations for polymers used in ocular drug delivery. Front Med. 2022;8:1–25.
doi: 10.3389/fmed.2021.787644
Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, et al. Archway phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results. Ophthalmology. 2023;130:735–47.
pubmed: 36870451
doi: 10.1016/j.ophtha.2023.02.024
Sobha S. Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol. 2008;2:339.
doi: 10.2147/OPTH.S2617
Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 2014;6:OED.S16067.
doi: 10.4137/OED.S16067
Yang Y, Lockwood A. Topical ocular drug delivery systems: innovations for an unmet need. Exp Eye Res. 2022;218:109006.
pubmed: 35248559
doi: 10.1016/j.exer.2022.109006
Mazet R, Yaméogo JBG, Wouessidjewe D, Choisnard L, Gèze A. Recent advances in the design of topical ophthalmic delivery systems in the treatment of ocular surface inflammation and their biopharmaceutical evaluation. Pharmaceutics. 2020;12:1–56.
doi: 10.3390/pharmaceutics12060570
Opitz DL, Harthan JS. Review of azithromycin ophthalmic 1% solution (AzaSite®) for the treatment of ocular infections. Ophthalmol Eye Dis. 2012;4:OED.S7791.
doi: 10.4137/OED.S7791
Savaroglu G, Genc L. Determination of micelle formation of ketorolac tromethamine in aqueous media by acoustic measurements. Thermochim Acta. 2013;552:5–9.
doi: 10.1016/j.tca.2012.11.008
Acharya A, Goudanavar P, Chitti R, Dinnimath BM. Preparation of gellan gum and chitosan based in-situ gel of timolol maleate for ophthalmic drug delivery and evaluation of physicochemical properties and drug release profile. Acta Sci Pharm Sci. 2019;3:68–78.
Agrawal P, Bhardwaj P. Glaucoma drainage implants. Int J Ophthalmol. 2020;13:1318.
pubmed: 32821688
pmcid: 7387917
doi: 10.18240/ijo.2020.08.20
King AJ, Shah A, Nikita E, Hu K, Mulvaney CA, Stead R, et al. Subconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma. Cochrane Database Syst Rev. 2018;12. https://doi.org/10.1002/14651858.CD012742.pub2